Experience With Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration

BACKGROUND AND OBJECTIVE: Describe visual and anatomic outcomes of eyes with exudative age-related macular degeneration (AMD) after treatment with aflibercept. PATIENTS AND METHODS: Eyes treated with intravitreal injections of aflibercept for exudative AMD were retrospectively reviewed to compare visual acuity and central subfield thickness (CST) on optical coherence tomography. RESULTS: A total of 142 eyes receiving aflibercept were previously treated with bevacizumab or ranibizumab intravitreal injections. Baseline vision was 20/73 +/- 5.18 lines when switched to aflibercept. It improved by 0.2 +/- 1.91 lines (P =. 14) after three injections but decreased by 0.45 +/- 2.9 lines (P =.06) after 1 year of follow-up. The reduction in CST was 9.9 +/- 46.5 mu m (P =.06) after three injections and grew to 19.3 +/- 50.6 mu m (P =.002), a statistically significant amount, after 1 year. CONCLUSION: Switching to aflibercept resulted in no clinically significant differences in visual acuity after 1 year. There was a significant reduction in CST, but this may not be clinically significant.